Cardiometabolic Health Solutions With GLP-1 Therapy

Discover the impact of GLP-1 therapy on cardiometabolic health and how it can benefit individuals seeking better wellness.

Abstract: A New Paradigm in Metabolic Health

Welcome to our educational post on the revolutionary class of medications known as GLP-1 receptor agonists. As a practitioner deeply rooted in integrative and functional medicine, with a diverse background spanning chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), my primary goal has always been to find the most effective, evidence-based strategies to improve my patients’ health. My clinical observations at our El Paso and San Antonio clinics, coupled with the latest research, continually point toward a more integrated and holistic approach to chronic disease. This post will serve as your guide, translating complex clinical trials and physiological mechanisms into an easy-to-understand narrative. We will delve into how these powerful agents work, explore the landmark cardiovascular outcomes trials (CVOTs) that revealed their ability to protect the heart and kidneys, and differentiate among the available options, such as semaglutide (Ozempic/Wegovy) and the dual-agonist tirzepatide (Mounjaro/Zepbound). Furthermore, we will delve into the practical aspects of using these therapies, including managing side effects, understanding safety considerations, and exploring their investigational uses in everything from neuroprotection to fertility. Most importantly, we’ll connect these pharmacological advancements back to the core principles of integrative health, examining how integrative chiropractic care is essential for maximizing patient outcomes and achieving true, sustainable well-being.

Rethinking Diabetes: Beyond Glucose-Centric Care

In my years of practice, I’ve seen firsthand the devastating impact of diabetes on my patients’ lives. For decades, the management of type 2 diabetes was primarily focused on lowering blood glucose levels. However, we now understand that this is only one piece of a much larger puzzle. It’s a reality underscored by stark statistics. We know that atherosclerotic cardiovascular disease (ASCVD)—which encompasses coronary heart disease, stroke, and peripheral arterial disease—is the leading cause of death for individuals with type 2 diabetes. In fact, more than 70% of elderly patients with diabetes will likely succumb to heart disease or a stroke. The prognosis following a heart attack is significantly poorer for someone with diabetes compared to someone without, and alarmingly, these outcomes often remain bleak even when blood glucose levels are considered “well-controlled.”
This has forced a critical shift in our clinical strategy. The old model, which I call the “glucose-centric” approach, is no longer sufficient. We must move toward a multifaceted management plan that reduces overall risk. This requires a collaborative and integrative effort.

Pillars of Modern Diabetes Management

The world’s leading medical bodies, including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease Improving Global Outcomes (KDIGO) group, are all aligned on this new, comprehensive approach. It’s no longer just about the A1c. Our focus must be on:
Lifestyle Management: Foundational changes in diet and physical activity.
Diabetes Self-Management Education: Empowering patients with the knowledge to control their condition.
Cardiovascular Risk Reduction: Aggressively managing blood pressure, cholesterol (lipids), and, of course, glucose levels.
Weight Management: Addressing excess weight as a key driver of metabolic dysfunction.
Smoking Cessation: Eliminating a major accelerator of cardiovascular disease.
This holistic view is the cornerstone of effective, 21st-century care.

Clinical Case Study: The Challenge of “Over-Basalization”

To illustrate these concepts, let’s consider a case similar to many patients I see in my clinic. We’ll call her Naomi.
Naomi is a 66-year-old female who has been living with type 2 diabetes for 12 years. Despite being on a robust medication regimen, her health is not where it needs to be.
A1c: Her last A1c was 8.3%, well above the target of less than 7%.
Comorbidities: She has high cholesterol (hyperlipidemia), hypertension, and protein in her urine (proteinuria), a sign of early kidney stress.
Medications:
Metformin 1000 mg twice daily.
Degludec insulin (a basal insulin): 66 units daily.
An SGLT-2 inhibitor (a class of oral diabetes medication).
A statin for cholesterol.
An ARB for blood pressure.
Weight: She weighs 220 pounds and is 5’9 “, giving her a BMI of 32.5, placing her in the obese category.
Glucose Readings:
Her fasting glucose levels are between 140 and 160 mg/dL. The goal is typically 90-130 mg/dL.
Her postprandial (after-meal) glucose levels are 160-170 mg/dL. While the ADA goal is under 180 mg/dL, many specialists, including myself, prefer to see this number much lower, ideally under 140 mg/dL two hours after a meal.

The Problem: Over-Basalized and Still Not at Goal

Naomi’s case highlights a common clinical problem: “over-basalization.” She is taking a very high dose of basal insulin, yet her A1c and fasting glucose are still too high. A simple clinical calculation I use is to multiply a patient’s weight in kilograms by 0.5. For Naomi, who weighs 100 kg, this suggests that a basal insulin dose above 50 units may be excessive. At 66 units, she is clearly over-basalized.
The high basal insulin dose isn’t effectively controlling her blood sugar, and it’s likely contributing to her difficulty with weight management. The logical next step in a traditional model might be to add prandial (mealtime) insulin to cover her post-meal glucose spikes. However, this is where we can intervene more intelligently. Before adding more insulin, which often leads to further weight gain and increased risk of hypoglycemia, we should consider a GLP-1 receptor agonist. This approach leverages the body’s natural “incretin effect” to address the very issue Naomi is struggling with: postprandial hyperglycemia.

Understanding GLP-1 Receptor Agonists: The Incretin Effect

To truly appreciate these medications and understand why a GLP-1 agent is such a powerful tool, we need to talk about the “incretin effect.” This term describes a fascinating physiological process that is glucose-dependent, meaning these hormones act primarily when glucose is present. Our bodies naturally produce incretin hormones, specifically GLP-1 (Glucagon-Like Peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which are synthesized and released by specialized “L-cells” in the jejunum, a part of our small intestine.
This release is triggered by the presence of food in the gut. When you eat a meal, these hormones are secreted into the bloodstream, orchestrating a multi-pronged response:
Stimulates Insulin Secretion: It signals the pancreas to increase insulin secretion, but only in a glucose-dependent manner. This means it only works when blood sugar is high, dramatically reducing the risk of hypoglycemia compared to insulin or other medications.
Suppresses Glucagon Release: It signals the pancreas to stop releasing glucagon, a hormone that prompts the liver to produce more glucose. This prevents unnecessary glucose from entering the bloodstream.
Slows Gastric Emptying: It slows down the rate at which food leaves the stomach. This makes you feel full sooner and for longer, helping to control appetite and prevent sharp, rapid spikes in blood sugar after meals.
Promotes Satiety: It acts directly on the brain to reduce appetite and increase feelings of fullness.
In individuals with type 2 diabetes, this natural incretin effect is often blunted or, in some cases, completely absent. They produce very low levels of their native GLP-1 hormone. This deficiency leads to insufficient insulin secretion after meals and a failure to suppress glucagon. The result is the hallmark hyperglycemia we see in diabetes. GLP-1 receptor agonists are medications designed to mimic the action of our own GLP-1, but they are engineered to last much longer in the body, restoring and amplifying these beneficial effects.

Mechanisms of Action: More Than Just Blood Sugar Control

The mechanisms of these drugs are multifaceted and explain not only their benefits but also their common side effects.
Gastrointestinal System: In the presence of a GLP-1 agonist, gastric emptying is significantly slowed. This delay is a primary reason patients feel full for longer, which naturally leads to reduced food intake and contributes to weight loss. Unfortunately, this slowing effect can also cause side effects like mild nausea and occasionally vomiting, especially in individuals with a history of gastroparesis. Some patients may experience diarrhea, while others report constipation or mild abdominal pain.
Central Nervous System (Brain): We believe that these small-molecule drugs can cross the blood-brain barrier and act directly on the brain’s appetite centers, such as the hypothalamus. This central action helps to decrease appetite and reduce food cravings, providing another powerful mechanism for weight loss. The feeling of prolonged satiety is likely a combination of this central effect and the delayed gastric emptying.
Pancreas: In the pancreas, GLP-1 agonists stimulate glucose-dependent insulin secretion from the beta cells. Simultaneously, they suppress glucagon secretion. By lowering glucagon, they help reduce the liver’s inappropriate production and release of stored glucose, a common dysfunction in type 2 diabetes.

The “Ominous Octet” and the Power of GLP-1s

In 2009, the renowned endocrinologist Dr. Ralph DeFronzo published a seminal paper describing the “Ominous Octet”—eight core pathophysiological defects that contribute to type 2 diabetes (DeFronzo, 2009). This framework helps us understand the complexity of the disease. What is remarkable is that GLP-1 receptor agonists address six of these eight defects very effectively. Their widespread use makes them among the most comprehensive therapies available.

Choosing the Right GLP-1 Agonist: A Comparative Look

The family of GLP-1 agents has grown, offering us a variety of options with distinct profiles. It’s crucial to choose an agent that aligns with the individual patient’s needs. Let’s look at the data from leading researchers to understand the impact of these medications. When we compare these agents, we see a clear progression in efficacy:
Liraglutide resulted in a weight loss of about 2.7 kilograms and a just under 1% reduction in HbA1c.
Dulaglutide improved upon this, showing an average weight loss of 4.6 kilograms.
Semaglutide represented a significant leap forward, demonstrating an average weight loss of 6.4 kilograms and a more robust HbA1c reduction of between 1.8% and 2.1%.
Then came tirzepatide, a dual GIP and GLP-1 receptor agonist, which has shown truly remarkable results. In clinical trials, it was associated with an average weight loss of 11.2 kilograms—almost double that of semaglutide—and an impressive 2.3% reduction in HbA1c.
It’s crucial to note that these powerful results, particularly for weight loss, were observed at the higher doses approved by the FDA during the drug approval process. Here’s a breakdown of the key players, based on the latest research and FDA indications as of May 21, 2026:
Medication (Brand Name)
Key Indications & Benefits
A1c Lowering
Typical Weight Loss
Semaglutide (Ozempic/Rybelsus)
Type 2 Diabetes, Weight Loss (Wegovy), MACE Reduction, Nephropathy Protection. Semaglutide is a potent agent with robust evidence of cardiovascular and kidney benefits.
~1.5-2.0%
~15% of body weight
Tirzepatide (Mounjaro/Zepbound)
Type 2 Diabetes, Weight Loss, OSA. This is a “twincretin,” a dual GLP-1/GIP agonist, showing the highest efficacy for both glucose lowering and weight loss. Cardiovascular outcome trials are ongoing but look promising.
>2.0%
>20% of body weight
Dulaglutide (Trulicity)
Type 2 Diabetes, MACE Reduction, Nephropathy Protection. A reliable weekly injection with proven cardiovascular and kidney benefits, though with more moderate weight loss compared to newer agents.
~1.0-1.5%
~3-5 kg
Liraglutide (Victoza)
Type 2 Diabetes, MACE Reduction, Nephropathy Protection. One of the first GLP-1s with proven cardiovascular benefits, but it requires a daily injection. Weight loss is more modest. A higher dose is available for weight loss (Saxenda).
~1.1%
~2.5 kg
Exenatide (Byetta/Bydureon)
Type 2 Diabetes. One of the earliest GLP-1s. It is effective for glucose control but has less impact on weight and lacks the proven cardiovascular protection of newer agents.
<1.0%
~2.9 kg
MACE = Major Adverse Cardiovascular Events (heart attack, stroke, cardiovascular death). OSA = Obstructive Sleep Apnea.
 
 
 
When I select a GLP-1 agonist for a patient, I’m not just looking at the A1c. For Naomi, who has hypertension and proteinuria, choosing an agent with proven MACE reduction and nephropathy protection like semaglutide (Ozempic) or dulaglutide (Trulicity) would be a critical part of a comprehensive strategy. Given her significant need for weight loss and A1c reduction, semaglutide or tirzepatide would be the top consideration.

Cardiovascular Outcomes Trials (CVOTs): The Game-Changer

The history of diabetes medications is marked by a pivotal moment in 2008. Following safety concerns with earlier drugs, the FDA mandated that all new diabetes drugs undergo large, long-term Cardiovascular Outcomes Trials (CVOTs). The goal was to demonstrate that these new drugs did not harm the cardiovascular system.
What happened next was completely unexpected and revolutionized our field. Not only were these drugs safe, but they also provided robust cardiovascular risk reduction. This discovery shifted the paradigm from “just diabetes drugs” to essential tools for cardiologists and nephrologists. The GLP-1 receptor agonists soon followed with their own impressive CVOT data:
REWIND Trial (Dulaglutide): Showed a 12% reduction in major adverse cardiovascular events (MACE).
LEADER Trial (Liraglutide): Showed a 13% reduction in MACE.
SUSTAIN-6 Trial (Subcutaneous Semaglutide): Showed a remarkable 26% reduction in MACE.
These large, multi-year, double-blind, placebo-controlled studies involving thousands of patients solidified the role of these medications as cornerstones of cardio-renal-metabolic care. We now view metabolic disease through the lens of the cardio-renal-metabolic (CRM) triad. These systems are bidirectionally linked; a problem in one inevitably affects the others.

How Professional Guidelines Position GLP-1 Agonists

The American Diabetes Association (ADA) has recognized the profound benefits of these medications. The 2025 ADA guidelines, published annually in Diabetes Care, place a strong emphasis on GLP-1 receptor agonists, especially for certain patient populations (ElSayed et al., 2024).
The ADA treatment algorithm is divided into two main pathways:
The Left-Hand Pathway: For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), or those at very high risk. For these patients, a GLP-1 receptor agonist is now strongly favored as a primary agent, sometimes even before metformin.
The Right-Hand Pathway: For patients whose primary needs are glycemic control and weight management but who do not have the high-risk cardiovascular or kidney profile.
For patients with CKD, SGLT2 inhibitors are often the first choice. However, certain GLP-1 agonists, specifically semaglutide, have also earned an indication for kidney protection. The FLOW trial, stopped early due to overwhelmingly positive results, demonstrated that semaglutide reduced the risk of major kidney disease events and cardiovascular death by 24% in people with type 2 diabetes and CKD.

Balancing Body and Metabolism- Video

Navigating the Switch: A Guide to Changing GLP-1 Agonists

As a clinician committed to patient-centered care, I often encounter scenarios in which a medication switch is considered. A recent case involved a patient, we’ll call her Tammy, who was on Trulicity (dulaglutide) but wasn’t achieving her desired weight loss. Through shared decision-making, we explored a switch. This requires a careful, evidence-informed approach.
Switching from Trulicity (dulaglutide) to Ozempic (semaglutide): To switch from a 1.5 mg dose of dulaglutide, I would begin her on semaglutide 0.5 mg weekly. This conservative start minimizes side effects. After a month, if she tolerates it well, we could increase her to a weekly dose of 1 mg.
Switching from Trulicity (dulaglutide) to Mounjaro (tirzepatide): After her last dose of Trulicity, we would wait a full week (a “washout” period) before starting tirzepatide. I would initiate treatment with tirzepatide 5 mg weekly. The goal is to find the optimal dose—the one where the patient achieves significant satiety and weight loss with minimal side effects—by titrating up every four weeks if needed.

The Expanding Universe of GLP-1 Receptor Agonists

The story of GLP-1 agonists is no longer confined to diabetes. The research community is buzzing with discoveries about their far-reaching benefits.

Metabolically Associated Steatotic Liver Disease (MASLD)

One of the most promising frontiers is in liver health. The primary benefit for MASLD and its inflammatory progression, MASH, comes from the significant and sustained weight loss these drugs induce, which directly decreases fat deposition in the liver (Abbasi, 2024). Novo Nordisk is seeking FDA approval for this indication, which we may see by late 2025 or early 2026.

Expanding Indications: Beyond Diabetes

The benefits have proven to extend beyond patients with type 2 diabetes, as established by two landmark trials:
STEP-HFpEF Trial: This study showed that in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide led to significant improvements in heart failure symptoms and physical limitations, regardless of whether the patients had diabetes (Kosiborod et al., 2023).
SELECT Trial: This trial involved over 17,000 overweight or obese patients with pre-existing heart disease but without diabetes. The group receiving semaglutide showed a 20% reduction in MACE compared to placebo.

Cravings, Compulsive Behaviors, and Addiction

A consistent report from my own patients is a dramatic reduction in cravings. They describe it as a quieting of the constant “food noise” in their brain, with a decreased desire for alcohol and smoking. This points to a fundamental impact on the brain’s reward pathways.

PCOS, Fertility, and the “Ozempic Babies” Phenomenon

For many women with Polycystic Ovary Syndrome (PCOS), the substantial weight loss from these drugs can restore metabolic balance and regulate menstrual cycles. This has led to enhanced fertility and the recent media phenomenon of “Ozempic babies.”

Other Investigational Uses

Researchers are also observing positive effects in:
Neuroprotection: Patients with dementia and Parkinson’s disease have shown a stall in disease progression, suggesting a neuroprotective effect within the brain.
Latent Autoimmune Diabetes in Adults (LADA): The off-label use of GLP-1 agonists is being studied to help preserve remaining beta-cell function in this form of autoimmune diabetes (Buzzetti et al., 2020).
Respiratory Health: In patients with asthma and COPD, these drugs have been associated with fewer exacerbations, likely due to their anti-inflammatory properties.

The Role of Integrative Chiropractic Care

This is where my perspective as a DC, APRN, and Functional Medicine Practitioner becomes so important. While these medications are incredibly powerful, they are tools, not cures. True, lasting health is achieved when we combine these advanced pharmacotherapies with a foundation of lifestyle and structural wellness.
Optimizing Nervous System Function: The nervous system is the body’s master controller. The gut-brain axis is a two-way communication highway critical for satiety signaling. Chiropractic adjustments can help reduce nerve interference, potentially enhancing the body’s response to these signals and improving the efficiency of the gut-brain connection.
Supporting Musculoskeletal Health During Weight Loss: Rapid and significant weight loss can place new stresses on the body as a patient’s center of gravity shifts. This can lead to new patterns of musculoskeletal pain. Integrative chiropractic care is crucial for managing these biomechanical changes through targeted adjustments, soft-tissue work, and the prescription of corrective exercises.
Addressing the Root Causes: Functional medicine teaches us to ask “Why?” We use a holistic approach to craft personalized nutrition plans, develop sustainable exercise regimens that preserve muscle mass, and implement stress-management techniques to reduce cortisol levels.
Chiropractic care is not an alternative to these medications; it is a vital complement. By ensuring the body’s structure and nervous system function optimally, we create an environment in which these powerful drugs can work most effectively.

Safety, Side Effects, and Practical Recommendations

While transformative, these medications require careful management.

Common GI Side Effects

Nausea: This is the most common side effect, often linked to early satiety.
Constipation or Diarrhea: The effect on motility varies by individual.
Management Strategy: The key is to “start low and go slow.” I start patients on the lowest possible dose for at least a month before considering an increase.

Important Safety Issues

Gallbladder Events: Rapid weight loss can increase the risk of gallstones.
Acute Kidney Injury: Can occur from severe nausea and vomiting leading to dehydration. Staying well-hydrated is critical.
Pancreatitis: Though rare, patients with severe, persistent abdominal pain should seek immediate medical attention.
Surgical Considerations: Anesthesiology guidelines recommend stopping weekly GLP-1 agonists at least one to two weeks before a planned surgery to reduce the risk of aspirating stomach contents.
Muscle and Bone Mass: Significant weight loss involves some loss of lean muscle and bone. I work with patients to incorporate resistance training and ensure adequate protein intake.

Black Box Warning: Thyroid C-Cell Tumors

These medications carry a black box warning regarding the risk of thyroid C-cell tumors observed in rodent studies. While this link has not been established in humans, the drugs are contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Final Thoughts: A New Hope for Patients

The advent of modern GLP-1 receptor agonists has fundamentally changed the landscape of diabetes and metabolic care. For patients like Naomi, starting a GLP-1 agonist is not just about adding another medication; it’s about shifting her disease trajectory. It offers the potential to achieve her A1c goal, lose significant weight, reduce her reliance on insulin, and lower her risk of a future heart attack or stroke.
As healthcare providers, it is our responsibility to embrace a comprehensive, integrative approach. By combining the power of these advanced medications with the foundational principles of lifestyle medicine and chiropractic care, we can offer our patients a new level of hope and empower them to achieve a healthier, more vibrant future.

References

• Abbasi, J. (2024). Semaglutide reduces liver fat in adults with HIV and steatotic liver disease. JAMA, 331(11), 904.
• American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2024. Diabetes Care, 47(Supplement 1), S158–S178.
• Buzzetti, E., Tuomi, T., Mauricio, D., Pietropaolo, M., Korhonen, S., Polek, A., … & Leslie, R. D. (2020). Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes, 69(10), 2037-2047.
• Das, S. R., & Everett, B. M. (2021). GLP-1 receptor agonists and cardiovascular outcomes in type 2 diabetes. Journal of the American College of Cardiology, 77(14), 1801–1803.
• DeFronzo, R. A. (2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes, 58(4), 773–795.
• ElSayed, N. A., Cefalu, W. T., & Kahan, S. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1).
• Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102(5S), S1–S127.
• Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., … & STEP-HFpEF Trial Committees and Investigators. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 389(12), 1069-1084.
• Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl 1), 5–21.

SEO Tags: GLP-1 agonists, Semaglutide, Tirzepatide, Ozempic, Mounjaro, Wegovy, Zepbound, Type 2 Diabetes, Weight Loss, Cardiovascular Risk Reduction, Integrative Chiropractic Care, Functional Medicine, Dr. Alexander Jimenez, El Paso Chiropractor, A1c, Postprandial Glucose, Incretin Effect, Metabolic Health, Heart Health, Kidney Disease, CVOT, Ominous Octet, Gastric Emptying, Satiety, MASH, neuroprotection, PCOS, fertility, LADA, patient-centered care, cardio-renal-metabolic health, chiropractic adjustment, musculoskeletal health